2 Healthcare Growth Stocks Lagging the Market but Poised for Rebound
Intuitive Surgical and Vertex Pharmaceuticals, despite underperforming the broader market this year, present compelling growth opportunities for investors. Intuitive Surgical's 16% decline in 2024 reflects temporary tariff pressures rather than fundamental weaknesses. The robotics pioneer continues expanding its installed base of da Vinci surgical systems, with procedure volume growth driving recurring revenue through disposable instruments.
Vertex maintains its dominance in cystic fibrosis treatments while advancing promising pipeline candidates. Both companies demonstrate the rare combination of established market leadership and continued innovation potential that typically rewards long-term investors. Their current valuations may offer an attractive entry point before the next growth phase.
